CTOR 📈 Citius Oncology - Overview

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock •

CTOR: Cancer, Therapies, Oncology, Lymphoma, Treatments

Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. The company is headquartered in New York, New York.Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.

Additional Sources for CTOR Stock

CTOR Stock Overview

Market Cap in USD 116m
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
GiC Sub-Industry Life Sciences Tools & Services
IPO / Inception 2022-12-08

CTOR Stock Ratings

Growth 5y -67.7%
Fundamental -50.0%
Dividend -
Rel. Strength Industry -1755
Analysts 4/5
Fair Price Momentum 1.09 USD
Fair Price DCF -

CTOR Dividends

No Dividends Paid

CTOR Growth Ratios

Growth Correlation 3m -0.9%
Growth Correlation 12m -71.4%
Growth Correlation 5y -71.4%
CAGR 5y -97.09%
CAGR/Mean DD 5y -1.69
Sharpe Ratio 12m -1.26
Alpha -127.25
Beta 1.23
Volatility 195.55%
Current Volume 199.1k
Average Volume 20d 182.8k
What is the price of CTOR stocks?
As of January 10, 2025, the stock is trading at USD 1.18 with a total of 199,100 shares traded.
Over the past week, the price has changed by -0.84%, over one month by +0.00%, over three months by +24.87% and over the past year by -97.09%.
Is Citius Oncology a good stock to buy?
Probably not. Based on ValueRay Fundamental Analyses, Citius Oncology (NASDAQ:CTOR) is currently (January 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -49.96 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CTOR as of January 2025 is 1.09. This means that CTOR is currently overvalued and has a potential downside of -7.63%.
Is CTOR a buy, sell or hold?
Citius Oncology has received a consensus analysts rating of 4.00. Therefor, it is recommend to buy CTOR.
  • Strong Buy: 0
  • Buy: 1
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0
What are the forecast for CTOR stock price target?
According to ValueRays Forecast Model, CTOR Citius Oncology will be worth about 1.2 in January 2026. The stock is currently trading at 1.18. This means that the stock has a potential upside of +3.39%.
Issuer Forecast Upside
Wallstreet Target Price - -
Analysts Target Price - -
ValueRay Target Price 1.2 3.4%